ClinicalTrials.gg
CompletedNCT05564117OASIS 4Updated Feb 25, 2026Results posted

Research Study Looking at How Well Semaglutide Tablets Taken Once Daily Work in People Who Have a Body Weight Above the Healthy Range

A Phase 3 interventional study of Semaglutide and Placebo semaglutide in Overweight and Obesity, sponsored by Novo Nordisk A/S. Completed at 23 sites in 4 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-02-25.

Primary conditionObesityRegistry: OverweightReclassifiedWhy we changed it
Registry
Overweight — the first condition term the registry derived for this study.
ClinicalTrials.gg
Obesity
Why
  1. The study's listed conditions name Obesity, a narrower term within Overweight.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Novo Nordisk A/S · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
307
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 143 studies testing semaglutide in Obesity — 68 open to participants now, 77 under way, 14 of them phase 3. Semaglutide · Obesity.

Enrollment
28th of 143
307 · median 100
Started
2022
with 18 others
Phase 3
42 of 143
10 open now
Registered
53rd of 143
by date
Lead sponsor
41 of 143
Novo Nordisk A/S

Among the 143 studies testing semaglutide in Obesity, this one is the 28th largest by enrollment, is one of 19 that started in 2022, is one of 42 in phase 3, and was the 53rd registered.

Obesity

11,543 studies on the registry are indexed under Obesity; 2,047 are open to participants now.

Browse Obesity studies →

Open to participants now

68 of the 143 studies testing semaglutide in Obesity are open now, in 12 countries. Recruiting first, the newest first:

63 more — sign in →

By country, each count listing its studies:

All 68 open studies →

About semaglutide

Semaglutide: first FDA approval 2017 (OZEMPIC), first EMA approval 2018. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 1,342 Obesity studies recruiting now, 377 (28%) set no upper age limit and 861 (64%) stop at 75 or younger; 168 take children under 18; 489 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 143 studies testing semaglutide in Obesity, or all of them as a file.
02

Study summary

This study will look how well semaglutide tablets taken once daily helps people with body weight above the healthy range. Participants will either get semaglutide 25 milligram (mg) once daily or placebo once daily. This study will last for 72 weeks, which includes 1-week screening period, 64 weeks of treatment period and 7 weeks of follow up period.

03

Conditions studied

  • Overweight
  • Obesity

Browse trials for

04

In context

Obesity Reclassified

11,543 studies on the registry are indexed under Obesity; 2,047 are open to participants now.

This study's enrollment of 307 is above the median of 67 across 9,023 interventional studies indexed under Obesity.

Browse Obesity studies →

Lead sponsor

Novo Nordisk A/S is the lead sponsor of 1,408 studies on the registry; 105 are open to participants now.

Of its 205 completed or terminated interventional studies of FDA-regulated products, 101 (49%) have results posted.

Compared within Obesity, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Overweight. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • obtained before any study-related activities. Study-related activities are any procedures that are carried out as part of the study, including activities to determine suitability for the study
  • Male or female, age greater than or equal to 18 years at the time of signing informed consent
  • (BMI) of
  • Greater than or equal to 27.0 kg/m\^2 with the presence of at least one of the following weight-related complications (treated or untreated): hypertension, dyslipidaemia, obstructive sleep apnoea or cardiovascular (CV) disease OR
  • Greater than or equal to 30.0 kg/m\^2
  • History of at least one self-reported unsuccessful dietary effort to lose body weight

Exclusion criteria

Exclusion Criteria:

  • A self-reported change in body weight greater than 5 kg (11 pound [lbs]) within 90 days before screening irrespective of medical records
  • greater than or equal to 6.5 percent (48 mmol/mol) as measured by the central laboratory at screening
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

06

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
307 participants (actual)

Study arms

  • Experimental
    Oral semaglutide 25 mg

    Participants will receive semaglutide tablets orally once daily. Participants will receive semaglutide in a dose escalation manner for 64 weeks: 3 mg (weeks 0 to 4), 7 mg (weeks 5 to 8), 14 mg (weeks 9 to 12), and 25 mg (weeks 13 to 64).

    Drug: Semaglutide

  • Placebo comparator
    Oral semaglutide placebo

    Participants will receive placebo tablets matched to semaglutide orally once daily for 64 weeks.

    Drug: Placebo semaglutide

Interventions

  • Semaglutide tablets orally once daily for 64 weeks.

  • DrugPlacebo semaglutide

    Semaglutide placebo-matching tablets orally once daily for 64 weeks.

07

What researchers measure

Primary outcomes

  1. Percentage Change in Body Weight

    Percentage change in body weight from baseline (week 0) to end of treatment (week 64) is presented.

    Time frame: Baseline (week 0), end of treatment (week 64)

  2. Number of Participants Who Achieved Body Weight Reduction Greater Than or Equal to (≥) 5% (Yes/No)

    Number of participants who achieved ≥5% body weight reduction at the end of treatment (week 64) from baseline (week 0) is presented. In the reported data, 'Yes' infers the number of participants who have achieved greater than or equal to 5% weight reduction, whereas 'No' infers the number of participants who have not achieved greater than or equal to 5% weight reduction.

    Time frame: At end of treatment (week 64)

Secondary outcomes

  1. Number of Participants Who Achieved Body Weight Reduction ≥ 10% (Yes/No)

    Number of participants who achieved ≥ 10% weight reduction at end of treatment (week 64) from baseline (week 0) is presented. In the reported data, 'Yes' infers the number of participants who have achieved greater than or equal to 10% weight reduction, whereas 'No' infers the number of participants who have not achieved greater than or equal to 10% weight reduction.

    Time frame: At end of treatment (week 64)

  2. Number of Participants Who Achieved Body Weight Reduction ≥ 15% (Yes/No)

    Number of participants who achieved ≥ 15% weight reduction at end of treatment (week 64) from baseline (week 0) is presented. In the reported data, 'Yes' infers the number of participants who have achieved greater than or equal to 15% weight reduction, whereas 'No' infers the number of participants who have not achieved greater than or equal to 15% weight reduction.

    Time frame: At end of treatment (week 64)

  3. Number of Participants Who Achieved Body Weight Reduction ≥ 20% (Yes/No)

    Number of participants who achieved ≥ 20% weight reduction at end of treatment (week 64) from baseline (week 0) is presented. In the reported data, 'Yes' infers the number of participants who have achieved greater than or equal to 20% weight reduction, whereas 'No' infers the number of participants who have not achieved greater than or equal to 20% weight reduction.

    Time frame: At end of treatment (week 64)

  4. Change in Physical Function Domain (5-items) Score Impact of Weight on Quality of Life-Lite for Clinical Trials (IWQOL-Lite for CT)

    Change in physical function domain score IWQOL-Lite-CT from baseline (week 0) to the end of treatment (week 64) is presented. IWQOL-Lite-CT is a 20-item obesity-specific PRO measures used to assess the impact of body weight changes on patient's physical (7 items, where 5 of the items comprise the physical functioning sub-domain) and psychosocial functioning (13 items) in 3 composite scores (Physical Function, Physical and Psychosocial) and a Total score, all ranging from 0 to 100 with higher scores reflecting better levels of functioning. This outcome measure shows results for 'physical function domain'.

    Time frame: Baseline (week 0), end of treatment (week 64)

  5. Number of Participants Who Achieved ≥14.6 IWQOL-Lite-CT Physical Function Domain (PFD) Score (Yes/No)

    Number of participants who achieved ≥14.6 in IWQOL-Lite-CT PFD score (Yes/No) from baseline to end of treatment (week 64) is presented. IWQOL-Lite-CT is a 20-item obesity-specific PRO measures used to assess the impact of body weight changes on patient's physical (7 items, where 5 of the items comprise the physical functioning sub-domain) and psychosocial functioning (13 items) in 3 composite scores (Physical Function, Physical and Psychosocial) and a Total score, all ranging from 0 to 100 with higher scores reflecting better levels of functioning.

    Time frame: Baseline (week 0), end of treatment (week 64)

  6. Change in Body Weight - Kilogram (kg)

    Change in body weight from baseline (week 0) to end of treatment (week 64) is presented.

    Time frame: Baseline (week 0), end of treatment (week 64)

  7. Change in Body Mass Index (BMI)

    Change in BMI from baseline (week 0) to end of treatment (week 64) is presented.

    Time frame: Baseline (week 0), end of treatment (week 64)

  8. Change in Waist Circumference

    Change in waist circumference from baseline (week 0) to end of treatment (week 64) is presented.

    Time frame: Baseline (week 0), end of treatment (week 64)

  9. Change in Systolic Blood Pressure

    Change in systolic blood pressure from baseline (week 0) to end of treatment (week 64) is presented.

    Time frame: Baseline (week 0), end of treatment (week 64)

  10. Change in Diastolic Blood Pressure

    Change in diastolic blood pressure from randomisation (week 0) to end of treatment (week 64) is presented.

    Time frame: Randomisation (week 0), end of treatment (week 64)

  11. Change in Glycosylated Haemoglobin (HbA1c)

    Change in HbA1c from baseline (week 0) to end of treatment (week 64) is presented.

    Time frame: Baseline (week 0), end of treatment (week 64)

  12. Change in Total Cholesterol - Ratio to Baseline

    Change in total cholesterol (measured in millimoles per liter \[mmol/L\]) from baseline (week 0) to end of treatment (week 64) is presented as ratio to baseline (week 0).

    Time frame: Baseline (week 0), end of treatment (week 64)

  13. Change in High Density Lipoprotein (HDL) Cholesterol - Ratio to Baseline

    Change in high density lipoprotein (HDL) cholesterol (measured in mmol/L) from baseline (week 0) to end of treatment (week 64) is presented as ratio to baseline (week 0).

    Time frame: Baseline (week 0), end of treatment (week 64)

  14. Change in Low Density Lipoprotein (LDL) Cholesterol - Ratio to Baseline

    Change in low density lipoprotein (LDL) cholesterol (measured in mmol/L) from baseline (week 0) to end of treatment (week 64) is presented as ratio to baseline (week 0).

    Time frame: Baseline (week 0), end of treatment (week 64)

  15. Change in Very Low-Density Lipoproteins (VLDL) Cholesterol - Ratio to Baseline

    Change in VLDL cholesterol (measured in mmol/L) from baseline (week 0) to end of treatment (week 64) is presented as ratio to baseline (week 0).

    Time frame: Baseline (week 0), end of treatment (week 64)

  16. Change in Triglycerides - Ratio to Baseline

    Change in triglycerides (measured in mmol/L) from baseline (week 0) to end of treatment (week 64) is presented as ratio to baseline (week 0).

    Time frame: Baseline (week 0), end of treatment (week 64)

  17. Change in Free Fatty Acids - Ratio to Baseline

    Change in free fatty acids (measured in mmol/L) from baseline (week 0) to end of treatment (week 64) is presented as ratio to baseline (week 0).

    Time frame: Baseline (week 0), end of treatment (week 64)

  18. Change in High Sensitivity C-Reactive Protein (hsCRP) - Ratio to Baseline

    Change in high sensitivity C-Reactive Protein (hsCRP) (milligram per litre \[mg/L\]) from baseline (week 0) to end of treatment (week 64) is presented as ratio to baseline (week 0).

    Time frame: Baseline (week 0), end of treatment (week 64)

  19. Change in Fasting Plasma Glucose (FPG)

    Change in FPG measured in milligrams per deciliter (mg/dL) from baseline (week 0) to end of treatment (week 64) is presented.

    Time frame: Baseline (week 0), end of treatment (week 64)

  20. Change in Fasting Serum Insulin - Ratio to Baseline

    Change in fasting serum insulin measured in picomoles per liter (pmol/L) from baseline (week 0) to end of treatment (week 64) is presented as ratio to baseline (week 0).

    Time frame: Baseline (week 0), end of treatment (week 64)

  21. Number of Participants With Body Mass Index (BMI) Less Than (<) 30 at Week 64 (Yes/no)

    Number of participants with BMI \<30 at the end of treatment (week 64) from baseline (week 0) is presented. The outcome measure is applicable for participants with BMI ≥ 30 at baseline (week 0). In the reported data, 'Yes' infers the number of participants who have achieved BMI less than 30, whereas 'No' infers the number of participants who have not achieved BMI less than 30 at week 64.

    Time frame: From baseline (week 0) to end of treatment (week 64)

  22. Number of Participants With Change in Glycaemic Status

    Number of participants with change in glycaemic status from baseline (week 0) to the end of treatment (week 64) is presented. These categories were set as per the following criteria: 1) Normo-glycaemia: glycated haemoglobin (HbA1c) \<5.7%; 2) Pre-diabetes: 5.7% \<= HbA1c \< 6.5% 3) Type 2 diabetes: HbA1c \>=6.5%.

    Time frame: Baseline (week 0), end of treatment (week 64)

  23. Number of Treatment Emergent Adverse Events (TEAEs)

    Number of treatment emergent adverse events from baseline (week 0) to end of study (week 71) is presented. An adverse event (AE) is defined as any untoward medical occurrence in a clinical study participant that is temporally associated with the use of investigational medicinal product (IMP), whether or not considered related to the IMP.

    Time frame: From baseline (week 0) to end of study (week 71)

  24. Number of Serious Treatment Emergent Adverse Events

    Number of treatment emergent serious adverse events from baseline (week 0) to end of study (week 71) is presented. A serious adverse event (SAE) is any untoward medical occurrence that fulfils at least one of following criteria: results in death; is life-threatening; requires inpatient or prolongation of existing hospitalization; results in persistent or significant disability/incapacity; is congenital anomaly/birth defect; important medical event.

    Time frame: From baseline (week 0) to end of study (week 71)

  25. Change in Pulse

    Change in pulse from baseline (week 0) to end of treatment (week 64) is presented.

    Time frame: Baseline (week 0), end of treatment (week 64)

08

Results

Posted Feb 25, 2026

Participant flow

The trial was conducted at 22 sites in 4 countries (Canada, Germany, Poland, and United States).

Participant flow — Overall Study
MilestoneOral Semaglutide 25 mgPlacebo
Started205102
Full analysis set205102
Safety analysis set204102
Completed19694
Not completed98
Withdrew: Withdrawal by subject11
Withdrew: Lost to follow-up77
Withdrew: Physician decision10

Outcome measures

PrimaryPercentage Change in Body Weight

Percentage change in body weight from baseline (week 0) to end of treatment (week 64) is presented.

Time frame:
Baseline (week 0), end of treatment (week 64)
Reported as:
Mean · Percentage change in body weight
Percentage Change in Body Weight
Percentage change in body weightOral Semaglutide 25 mgPlacebo
Percentage Change in Body Weight-14.4 ± 10.5-2.5 ± 7.9
Statistical analysis
  • Oral Semaglutide 25 mg vs Placebo · ANCOVA · p = <0.0001 · Treatment difference: -11.43 · 95% CI -13.88 to -8.98
  • Oral Semaglutide 25 mg vs Placebo · Mixed model for repeated measures (MMRM) · p = <0.0001 · Treatment difference: -13.87 · 95% CI -16.53 to -11.21
PrimaryNumber of Participants Who Achieved Body Weight Reduction Greater Than or Equal to (≥) 5% (Yes/No)

Number of participants who achieved ≥5% body weight reduction at the end of treatment (week 64) from baseline (week 0) is presented. In the reported data, 'Yes' infers the number of participants who have achieved greater than or equal to 5% weight reduction, whereas 'No' infers the number of participants who have not achieved greater than or equal to 5% weight reduction.

Time frame:
At end of treatment (week 64)
Reported as:
Count of participants · Participants
Number of Participants Who Achieved Body Weight Reduction Greater Than or Equal to (≥) 5% (Yes/No)
ParticipantsOral Semaglutide 25 mgPlacebo
Yes15228
No4062
Statistical analysis
  • Oral Semaglutide 25 mg vs Placebo · Regression, Logistic · p = <0.0001 · Treatment odds ratio: 7.34 · 95% CI 4.22 to 12.76
  • Oral Semaglutide 25 mg vs Placebo · Regression, Logistic · p = <0.0001 · Treatment odds ratio: 25.23 · 95% CI 13.24 to 48.07
SecondaryNumber of Participants Who Achieved Body Weight Reduction ≥ 10% (Yes/No)

Number of participants who achieved ≥ 10% weight reduction at end of treatment (week 64) from baseline (week 0) is presented. In the reported data, 'Yes' infers the number of participants who have achieved greater than or equal to 10% weight reduction, whereas 'No' infers the number of participants who have not achieved greater than or equal to 10% weight reduction.

Time frame:
At end of treatment (week 64)
Reported as:
Count of participants · Participants
Number of Participants Who Achieved Body Weight Reduction ≥ 10% (Yes/No)
ParticipantsOral Semaglutide 25 mgPlacebo
Yes12113
No7177
SecondaryNumber of Participants Who Achieved Body Weight Reduction ≥ 15% (Yes/No)

Number of participants who achieved ≥ 15% weight reduction at end of treatment (week 64) from baseline (week 0) is presented. In the reported data, 'Yes' infers the number of participants who have achieved greater than or equal to 15% weight reduction, whereas 'No' infers the number of participants who have not achieved greater than or equal to 15% weight reduction.

Time frame:
At end of treatment (week 64)
Reported as:
Count of participants · Participants
Number of Participants Who Achieved Body Weight Reduction ≥ 15% (Yes/No)
ParticipantsOral Semaglutide 25 mgPlacebo
Yes965
No9685
SecondaryNumber of Participants Who Achieved Body Weight Reduction ≥ 20% (Yes/No)

Number of participants who achieved ≥ 20% weight reduction at end of treatment (week 64) from baseline (week 0) is presented. In the reported data, 'Yes' infers the number of participants who have achieved greater than or equal to 20% weight reduction, whereas 'No' infers the number of participants who have not achieved greater than or equal to 20% weight reduction.

Time frame:
At end of treatment (week 64)
Reported as:
Count of participants · Participants
Number of Participants Who Achieved Body Weight Reduction ≥ 20% (Yes/No)
ParticipantsOral Semaglutide 25 mgPlacebo
Yes573
No13587
SecondaryChange in Physical Function Domain (5-items) Score Impact of Weight on Quality of Life-Lite for Clinical Trials (IWQOL-Lite for CT)

Change in physical function domain score IWQOL-Lite-CT from baseline (week 0) to the end of treatment (week 64) is presented. IWQOL-Lite-CT is a 20-item obesity-specific PRO measures used to assess the impact of body weight changes on patient's physical (7 items, where 5 of the items comprise the physical functioning sub-domain) and psychosocial functioning (13 items) in 3 composite scores (Physical Function, Physical and Psychosocial) and a Total score, all ranging from 0 to 100 with higher scores reflecting better levels of functioning. This outcome measure shows results for 'physical function domain'.

Time frame:
Baseline (week 0), end of treatment (week 64)
Reported as:
Mean · Score on a scale
Change in Physical Function Domain (5-items) Score Impact of Weight on Quality of Life-Lite for Clinical Trials (IWQOL-Lite for CT)
Score on a scaleOral Semaglutide 25 mgPlacebo
Change in Physical Function Domain (5-items) Score Impact of Weight on Quality of Life-Lite for Clinical Trials (IWQOL-Lite for CT)16.8 ± 20.48.3 ± 16.7
SecondaryNumber of Participants Who Achieved ≥14.6 IWQOL-Lite-CT Physical Function Domain (PFD) Score (Yes/No)

Number of participants who achieved ≥14.6 in IWQOL-Lite-CT PFD score (Yes/No) from baseline to end of treatment (week 64) is presented. IWQOL-Lite-CT is a 20-item obesity-specific PRO measures used to assess the impact of body weight changes on patient's physical (7 items, where 5 of the items comprise the physical functioning sub-domain) and psychosocial functioning (13 items) in 3 composite scores (Physical Function, Physical and Psychosocial) and a Total score, all ranging from 0 to 100 with higher scores reflecting better levels of functioning.

Time frame:
Baseline (week 0), end of treatment (week 64)
Reported as:
Count of participants · Participants
Number of Participants Who Achieved ≥14.6 IWQOL-Lite-CT Physical Function Domain (PFD) Score (Yes/No)
ParticipantsOral Semaglutide 25 mgPlacebo
Yes10431
No8458
SecondaryChange in Body Weight - Kilogram (kg)

Change in body weight from baseline (week 0) to end of treatment (week 64) is presented.

Time frame:
Baseline (week 0), end of treatment (week 64)
Reported as:
Mean · kg
Change in Body Weight - Kilogram (kg)
kgOral Semaglutide 25 mgPlacebo
Change in Body Weight - Kilogram (kg)-15.0 ± 11.3-2.3 ± 8.2
SecondaryChange in Body Mass Index (BMI)

Change in BMI from baseline (week 0) to end of treatment (week 64) is presented.

Time frame:
Baseline (week 0), end of treatment (week 64)
Reported as:
Mean · Kilogram per square meter (kg/m^2)
Change in Body Mass Index (BMI)
Kilogram per square meter (kg/m^2)Oral Semaglutide 25 mgPlacebo
Change in Body Mass Index (BMI)-5.3 ± 4.0-0.9 ± 2.8
SecondaryChange in Waist Circumference

Change in waist circumference from baseline (week 0) to end of treatment (week 64) is presented.

Time frame:
Baseline (week 0), end of treatment (week 64)
Reported as:
Mean · centimeter (cm)
Change in Waist Circumference
centimeter (cm)Oral Semaglutide 25 mgPlacebo
Change in Waist Circumference-12.9 ± 12.3-3.1 ± 11.2
SecondaryChange in Systolic Blood Pressure

Change in systolic blood pressure from baseline (week 0) to end of treatment (week 64) is presented.

Time frame:
Baseline (week 0), end of treatment (week 64)
Reported as:
Mean · Millimeters of mercury (mmHg)
Change in Systolic Blood Pressure
Millimeters of mercury (mmHg)Oral Semaglutide 25 mgPlacebo
Change in Systolic Blood Pressure-7 ± 15-5 ± 15
SecondaryChange in Diastolic Blood Pressure

Change in diastolic blood pressure from randomisation (week 0) to end of treatment (week 64) is presented.

Time frame:
Randomisation (week 0), end of treatment (week 64)
Reported as:
Mean · mmHg
Change in Diastolic Blood Pressure
mmHgOral Semaglutide 25 mgPlacebo
Change in Diastolic Blood Pressure-3 ± 9-2 ± 10
SecondaryChange in Glycosylated Haemoglobin (HbA1c)

Change in HbA1c from baseline (week 0) to end of treatment (week 64) is presented.

Time frame:
Baseline (week 0), end of treatment (week 64)
Reported as:
Mean · Percentage of HbA1c
Change in Glycosylated Haemoglobin (HbA1c)
Percentage of HbA1cOral Semaglutide 25 mgPlacebo
Change in Glycosylated Haemoglobin (HbA1c)-0.3 ± 0.3-0.0 ± 0.2
SecondaryChange in Total Cholesterol - Ratio to Baseline

Change in total cholesterol (measured in millimoles per liter \[mmol/L\]) from baseline (week 0) to end of treatment (week 64) is presented as ratio to baseline (week 0).

Time frame:
Baseline (week 0), end of treatment (week 64)
Reported as:
Geometric mean · Ratio of total cholesterol
Change in Total Cholesterol - Ratio to Baseline
Ratio of total cholesterolOral Semaglutide 25 mgPlacebo
Change in Total Cholesterol - Ratio to Baseline0.96 ± 15.30.98 ± 16.4
SecondaryChange in High Density Lipoprotein (HDL) Cholesterol - Ratio to Baseline

Change in high density lipoprotein (HDL) cholesterol (measured in mmol/L) from baseline (week 0) to end of treatment (week 64) is presented as ratio to baseline (week 0).

Time frame:
Baseline (week 0), end of treatment (week 64)
Reported as:
Geometric mean · Ratio of HDL
Change in High Density Lipoprotein (HDL) Cholesterol - Ratio to Baseline
Ratio of HDLOral Semaglutide 25 mgPlacebo
Change in High Density Lipoprotein (HDL) Cholesterol - Ratio to Baseline1.04 ± 15.80.99 ± 13.7
SecondaryChange in Low Density Lipoprotein (LDL) Cholesterol - Ratio to Baseline

Change in low density lipoprotein (LDL) cholesterol (measured in mmol/L) from baseline (week 0) to end of treatment (week 64) is presented as ratio to baseline (week 0).

Time frame:
Baseline (week 0), end of treatment (week 64)
Reported as:
Geometric mean · Ratio of LDL
Change in Low Density Lipoprotein (LDL) Cholesterol - Ratio to Baseline
Ratio of LDLOral Semaglutide 25 mgPlacebo
Change in Low Density Lipoprotein (LDL) Cholesterol - Ratio to Baseline0.96 ± 24.00.99 ± 25.9
SecondaryChange in Very Low-Density Lipoproteins (VLDL) Cholesterol - Ratio to Baseline

Change in VLDL cholesterol (measured in mmol/L) from baseline (week 0) to end of treatment (week 64) is presented as ratio to baseline (week 0).

Time frame:
Baseline (week 0), end of treatment (week 64)
Reported as:
Geometric mean · Ratio of VLDL
Change in Very Low-Density Lipoproteins (VLDL) Cholesterol - Ratio to Baseline
Ratio of VLDLOral Semaglutide 25 mgPlacebo
Change in Very Low-Density Lipoproteins (VLDL) Cholesterol - Ratio to Baseline0.80 ± 38.90.92 ± 36.8
SecondaryChange in Triglycerides - Ratio to Baseline

Change in triglycerides (measured in mmol/L) from baseline (week 0) to end of treatment (week 64) is presented as ratio to baseline (week 0).

Time frame:
Baseline (week 0), end of treatment (week 64)
Reported as:
Geometric mean · Ratio of triglycerides
Change in Triglycerides - Ratio to Baseline
Ratio of triglyceridesOral Semaglutide 25 mgPlacebo
Change in Triglycerides - Ratio to Baseline0.80 ± 39.20.93 ± 36.0
SecondaryChange in Free Fatty Acids - Ratio to Baseline

Change in free fatty acids (measured in mmol/L) from baseline (week 0) to end of treatment (week 64) is presented as ratio to baseline (week 0).

Time frame:
Baseline (week 0), end of treatment (week 64)
Reported as:
Geometric mean · Ratio of free fatty acids
Change in Free Fatty Acids - Ratio to Baseline
Ratio of free fatty acidsOral Semaglutide 25 mgPlacebo
Change in Free Fatty Acids - Ratio to Baseline0.86 ± 64.20.95 ± 76.6
SecondaryChange in High Sensitivity C-Reactive Protein (hsCRP) - Ratio to Baseline

Change in high sensitivity C-Reactive Protein (hsCRP) (milligram per litre \[mg/L\]) from baseline (week 0) to end of treatment (week 64) is presented as ratio to baseline (week 0).

Time frame:
Baseline (week 0), end of treatment (week 64)
Reported as:
Geometric mean · Ratio of hsCRP
Change in High Sensitivity C-Reactive Protein (hsCRP) - Ratio to Baseline
Ratio of hsCRPOral Semaglutide 25 mgPlacebo
Change in High Sensitivity C-Reactive Protein (hsCRP) - Ratio to Baseline0.50 ± 111.90.91 ± 122.8
SecondaryChange in Fasting Plasma Glucose (FPG)

Change in FPG measured in milligrams per deciliter (mg/dL) from baseline (week 0) to end of treatment (week 64) is presented.

Time frame:
Baseline (week 0), end of treatment (week 64)
Reported as:
Mean · mg/dL
Change in Fasting Plasma Glucose (FPG)
mg/dLOral Semaglutide 25 mgPlacebo
Change in Fasting Plasma Glucose (FPG)-7.3 ± 10.80.1 ± 12.0
SecondaryChange in Fasting Serum Insulin - Ratio to Baseline

Change in fasting serum insulin measured in picomoles per liter (pmol/L) from baseline (week 0) to end of treatment (week 64) is presented as ratio to baseline (week 0).

Time frame:
Baseline (week 0), end of treatment (week 64)
Reported as:
Mean · Ratio of fasting serum insulin
Change in Fasting Serum Insulin - Ratio to Baseline
Ratio of fasting serum insulinOral Semaglutide 25 mgPlacebo
Change in Fasting Serum Insulin - Ratio to Baseline0.74 ± 57.91.03 ± 62.5
SecondaryNumber of Participants With Body Mass Index (BMI) Less Than (<) 30 at Week 64 (Yes/no)

Number of participants with BMI \<30 at the end of treatment (week 64) from baseline (week 0) is presented. The outcome measure is applicable for participants with BMI ≥ 30 at baseline (week 0). In the reported data, 'Yes' infers the number of participants who have achieved BMI less than 30, whereas 'No' infers the number of participants who have not achieved BMI less than 30 at week 64.

Time frame:
From baseline (week 0) to end of treatment (week 64)
Reported as:
Count of participants · Participants
Number of Participants With Body Mass Index (BMI) Less Than (<) 30 at Week 64 (Yes/no)
ParticipantsOral Semaglutide 25 mgPlacebo
Yes779
No10277
SecondaryNumber of Participants With Change in Glycaemic Status

Number of participants with change in glycaemic status from baseline (week 0) to the end of treatment (week 64) is presented. These categories were set as per the following criteria: 1) Normo-glycaemia: glycated haemoglobin (HbA1c) \<5.7%; 2) Pre-diabetes: 5.7% \<= HbA1c \< 6.5% 3) Type 2 diabetes: HbA1c \>=6.5%.

Time frame:
Baseline (week 0), end of treatment (week 64)
Reported as:
Count of participants · Participants
Number of Participants With Change in Glycaemic Status
ParticipantsOral Semaglutide 25 mgPlacebo
Normo-glycaemia (week 0) — Normo-glycaemia (week 64)9235
Normo-glycaemia (week 0) — Pre-diabetes (week 64)511
Normo-glycaemia (week 0) — Diabetes (week 64)00
Pre-diabetes (week 0) — Normo-glycaemia (week 64)6413
Pre-diabetes (week 0) — Pre-diabetes (week 64)2526
Pre-diabetes (week 0) — Diabetes (week 64)10
Diabetes (week 0) — Normo-glycaemia (week 64)00
Diabetes (week 0) — Pre-diabetes (week 64)30
Diabetes (week 0) — Diabetes (week 64)01
SecondaryNumber of Treatment Emergent Adverse Events (TEAEs)

Number of treatment emergent adverse events from baseline (week 0) to end of study (week 71) is presented. An adverse event (AE) is defined as any untoward medical occurrence in a clinical study participant that is temporally associated with the use of investigational medicinal product (IMP), whether or not considered related to the IMP.

Time frame:
From baseline (week 0) to end of study (week 71)
Reported as:
Number · Events
Number of Treatment Emergent Adverse Events (TEAEs)
EventsOral Semaglutide 25 mgPlacebo
Number of Treatment Emergent Adverse Events (TEAEs)1239432
SecondaryNumber of Serious Treatment Emergent Adverse Events

Number of treatment emergent serious adverse events from baseline (week 0) to end of study (week 71) is presented. A serious adverse event (SAE) is any untoward medical occurrence that fulfils at least one of following criteria: results in death; is life-threatening; requires inpatient or prolongation of existing hospitalization; results in persistent or significant disability/incapacity; is congenital anomaly/birth defect; important medical event.

Time frame:
From baseline (week 0) to end of study (week 71)
Reported as:
Number · Events
Number of Serious Treatment Emergent Adverse Events
EventsOral Semaglutide 25 mgPlacebo
Number of Serious Treatment Emergent Adverse Events1713
SecondaryChange in Pulse

Change in pulse from baseline (week 0) to end of treatment (week 64) is presented.

Time frame:
Baseline (week 0), end of treatment (week 64)
Reported as:
Mean · Beats per minute (Beats/min)
Change in Pulse
Beats per minute (Beats/min)Oral Semaglutide 25 mgPlacebo
Change in Pulse2 ± 101 ± 9

Adverse events

Collected over From week 0 to week 71. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Oral Semaglutide 25 mg0/205 (0%)8/204 (3.9%)172/204 (84.3%)
Placebo0/102 (0%)9/102 (8.8%)79/102 (77.5%)
Most frequent serious events
Showing 10 of 29
Most frequent serious events
EventOral Semaglutide 25 mgPlacebo
Acute kidney injuryRenal and urinary disorders0/2041/102
Adrenal neoplasmNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/2041/102
Cervical polypReproductive system and breast disorders0/2041/102
DepressionPsychiatric disorders0/2041/102
Fracture displacementInjury, poisoning and procedural complications0/2041/102
FuruncleInfections and infestations0/2041/102
HyponatraemiaMetabolism and nutrition disorders0/2041/102
HypotensionVascular disorders0/2041/102
OsteoarthritisMusculoskeletal and connective tissue disorders0/2041/102
Pancreatitis acuteGastrointestinal disorders0/2041/102
Most frequent other events
Showing 10 of 24
Most frequent other events
EventOral Semaglutide 25 mgPlacebo
NauseaGastrointestinal disorders95/20419/102
VomitingGastrointestinal disorders63/2046/102
NasopharyngitisInfections and infestations43/20427/102
COVID-19Infections and infestations41/20418/102
ConstipationGastrointestinal disorders41/20410/102
DyspepsiaGastrointestinal disorders37/2049/102
DiarrhoeaGastrointestinal disorders36/2049/102
HeadacheNervous system disorders24/2049/102
EructationGastrointestinal disorders21/2042/102
InfluenzaInfections and infestations15/20410/102

Baseline characteristics

FAS included all randomised participants. Participants were analysed according to the randomised treatment.

Age, Continuous
Age, Continuous(Years)Oral Semaglutide 25 mgPlaceboTotal
Mean48 ± 1347 ± 1348 ± 13
Sex: Female, Male
Sex: Female, Male(Participants)Oral Semaglutide 25 mgPlaceboTotal
Female15587242
Male501565
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Oral Semaglutide 25 mgPlaceboTotal
Hispanic or Latino17724
Not Hispanic or Latino18895283
Unknown or Not Reported000
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Oral Semaglutide 25 mgPlaceboTotal
American Indian or Alaska Native000
Asian112
Black or African American13922
Native Hawaiian or Other Pacific Islander000
White19091281
Other112
09

Study locations

23 sites
  • Univsty Of AL At Birmingham
    Birmingham, Alabama 35294, United States
  • FDRC
    Costa Mesa, California 92627, United States
  • East West Medical Research Institute_Honolulu
    Honolulu, Hawaii 96814, United States
  • Accellacare
    Wilmington, North Carolina 28401, United States
  • UT Southwestern Med Cntr
    Dallas, Texas 75390-9302, United States
  • Washington Cntr Weight Mgmt
    Arlington, Virginia 22206, United States
  • Selma Medical Associates
    Winchester, Virginia 22601, United States
  • G.A. Research Associates Ltd.
    Moncton, New Brunswick E1G 1A7, Canada
  • Wharton Med Clin Trials
    Hamilton, Ontario L8L 5G8, Canada
  • InnoDiab Forschung GmbH
    Essen, 45136, Germany
  • Diabetologische Gemeinschaftspraxis Dr. Staudenmeyer und Dr. Schiwietz
    Lingen, 49808, Germany
  • MedicalCenter am Clemenshospital - Schwerpunktpraxis für Diabetologie und Ernährungsmedizin
    Münster, 48153, Germany
  • RED-Institut für medizinische Forschung und Fortbildung GmbH
    Oldenburg in Holstein, 23758, Germany
  • Praxis Dr. med. Wenzl-Bauer
    Rehlingen-Siersburg, 66780, Germany
  • MZM Praxis Drs. Erlinger
    Stuttgart, 70378, Germany
  • Praxis für Prävention und Therapie, Drs Jacob
    Villingen-Schwenningen, 78048, Germany
  • Zentrum für klinische Studien Allgäu Oberschwaben
    Wangen, 88239, Germany
  • Beata Miklaszewicz&Dariusz Dabrowski "CARDIAMED" s.j.
    Legnica, Lower Silesian Voivodeship 59-220, Poland
  • ETG Lublin
    Lublin, Lublin Voivodeship 20-412, Poland
  • ETG Siedlce
    Siedlce, Masovian Voivodeship 08-110, Poland
  • ETG Warszawa Sp. z o.o.
    Warsaw, Masovian Voivodeship 02-677, Poland
  • Gabinet Leczenia Otylosci i Chorob Dietozaleznych
    Bialystok, Podlaskie Voivodeship 15-281, Poland
  • Centrum Zdrowia Metabolicznego
    Poznan, Wielkopolskie Voivodeship 60-589, Poland
10

References and documents

Publications

  • Wharton S, Lingvay I, Bogdanski P, Duque do Vale R, Jacob S, Karlsson T, Shaji C, Rubino D, Garvey WT; OASIS 4 Study Group. Oral Semaglutide at a Dose of 25 mg in Adults with Overweight or Obesity. N Engl J Med. 2025 Sep 18;393(11):1077-1087. doi: 10.1056/NEJMoa2500969. PubMed 40934115 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — According to the Novo Nordisk disclosure commitment on novonordisk-trials.com.

11

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Oct 2022 to primary completion in Apr 2024, 18 months.

Results were first posted in Feb 2026, 1 year 10 months after primary completion. A results delay was requested in Apr 2025.

Of 199 industry-sponsored phase 3 interventional studies under Obesity, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 27. This study's 18 months is below that.

Counting every sponsor, half of 262 studies reached it within 24 months; a quarter within 18 and three quarters within 34.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 29, 2022
First posted
Oct 3, 2022
StartActual
Oct 11, 2022
Primary completionActual
Apr 18, 2024
CompletionActual
May 7, 2024
Results delay requested
Apr 14, 2025
Results first posted
Feb 25, 2026
Last update
Feb 25, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 25, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
12

Registry details

Key details

Study ID
NCT05564117
Lead sponsor
Novo Nordisk A/S
Responsible party
Sponsor
First posted
Oct 3, 2022
Start date
Oct 11, 2022
Primary completion
Apr 18, 2024
Completion
May 7, 2024
Results posted
Feb 25, 2026
Last update
Feb 25, 2026

Study contacts

Clinical Transparency dept. 2834
study director · Novo Nordisk A/S

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Semaglutide

Start the discussion